GLYCOREX TRANSPLANTATION B

XeltisMedical DevicesNetherlands

69% match

Xeltis is a medical technology company that develops bioresorbable cardiovascular implants, such as artificial blood vessels and valves. Utilizing its proprietary Restorex technology, the company's products are designed to be gradually replaced by the patient's own living tissue to treat life-threatening conditions and improve vascular surgery outcomes.

OrganOxMedical DevicesUnited Kingdom

68% match

OrganOx is an organ technology company founded as a spin-out from the University of Oxford, United Kingdom. It pioneers liver perfusion technology to address transplant challenges and improve transplant success through innovation and clinical research.

Xvivo Perfusion AB (publ) is a specialized medtech company creating advanced technologies for the preservation and perfusion of organs, tissues, and cells, vital for successful transplantation. Founded in 1998 and headquartered in Gothenburg, Sweden, the company extends its operations across Sweden, the United States, the broader regions of North and South America, Europe, the Middle East, Africa, and the Asia Pacific. Their product line encompasses the XVIVO System (XPS), an integrated, off-the-shelf cardiac bypass system engineered for secure normothermic ex vivo lung perfusion (EVLP). Accompanying this is the XPS Disposable Lung Kit, supplying necessary sterile disposables and pre-packaged components. They also provide STEEN Solution, a uniquely formulated buffered extracellular solution optimized for perfusing isolated donor lungs during EVLP, and Perfadex Plus, an extracellular, low-potassium, dextran-based electrolyte solution for organ preservation. Additional offerings include the XVIVO Silicone Tubing Set for efficient flushing of donor lungs during procurement, as well as the XVIVO LS and XVIVO Disposable Lung Set, which together constitute a dedicated EVLP device. Furthermore, Xvivo Perfusion supplies the XVIVO Organ Chamber, a single-use sterile disposable container designed as a temporary holding unit for isolated lungs before transplantation, alongside the single-use, sterile XVIVO Lung Cannula Set.

Cytosorbents Corporation specializes in creating and bringing to market innovative medical devices. Their core expertise lies in a unique blood purification platform, built upon a proprietary adsorbent and porous polymer technology. The company's leading product, CytoSorb, is an extracorporeal filter designed to remove cytokines from the blood. It serves as a complementary treatment in various critical care scenarios, including sepsis, managing complications during and after heart bypass surgery, and improving the viability of donor organs for transplantation. Beyond CytoSorb, Cytosorbents offers a portfolio of specialized devices. These include VetResQ, used to assist in treating critical conditions like sepsis and pancreatitis in animals; CytoSorb-XL, another device targeting sepsis and other severe illnesses; HemoDefend, a platform for purifying blood supplies by removing contaminants that cause transfusion reactions and diseases, as well as anti-A and anti-B antibodies from blood products; K+ontrol, designed for patients with severe, life-threatening hyperkalemia; and ContrastSorb, which extracts intravenous contrast agents following imaging procedures (like CT scans, angiograms, or interventional radiology) to mitigate the risk of contrast-induced kidney damage. The company is also actively developing several new solutions: BetaSorb, aimed at preventing and treating complications from metabolic toxin buildup in chronic kidney disease patients; DrugSorb, which focuses on eliminating harmful chemicals from the bloodstream; and DrugSorb-ATR, an innovative system for removing antithrombotic agents. Originally established as MedaSorb Technologies Corporation in 1997, the company adopted its current name, Cytosorbents Corporation, in May 2010. Its corporate headquarters are situated in Princeton, New Jersey.

TransMedics Group, Inc.TMDX · Medical DevicesAndover, United States

65% matchPublicAI 4/100 ▲Green 0/100

TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.

OrthoxMedical DevicesUnited Kingdom

64% match

Orthox is a medical device company founded to transform how injuries to cartilage and other hard-to-heal human tissues are treated, with its headquarters located in Oxfordshire, United Kingdom.